Consensus NextCure, Inc.

Stocks

NXTC

US65343E2072

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2026-09-04 EDT			5-day change	1st Jan Change
7.820 ^USD	-0.26%		+28.41%	-44.89%

09-03	NextCure Enters Into Ninth Amendment To Lease Agreement And Vacates Premises At 8000 Virginia Manor Road	CI
08-12	RTW Biotech's Avere to go public in US in reverse merger with NextCure	AN

Evolution of the Average Target: NextCure, Inc.

Evolution of the Target Price: NextCure, Inc.

Changes in Analyst Recommendations: NextCure, Inc.

3ecface5150761f1ac95.c5LPZ3ub8CIaDHmxG9GqJ8JNQjKkAKi3gYBspqTEvhE.St-tEBjYgXEpdB3BXLr6a5B7DVCdcP3b6vMU-fCt6yg1x6kmFOiyUUlFFg~2b10dd13e53dcedfb24768a771d996ee

Analysts' recommendations: NextCure, Inc.

23-08-08	HC Wainwright Initiates NextCure With Buy Rating, $7 Price Target	MT
22-11-04	BTIG Lowers NextCure's Price Target to $8 From $27, Maintains Buy Rating	MT
22-11-04	Needham Lowers NextCure's Price Target to $6 From $12, Maintains Buy Rating	MT
22-11-04	Roth Capital Lowers NextCure's Price Target to $4 From $6, Maintains Neutral Rating	MT
22-11-04	Ladenburg Downgrades NextCure to Neutral From Buy	MT
22-11-04	Piper Sandler Adjusts Price Target on NextCure to $6 From $13, Maintains Overweight Rating	MT
22-08-23	Truist Securities Adjusts NextCure's Price Target to $15 From $19, Reiterates Buy Rating	MT
22-05-23	Piper Sandler Lowers NextCure's Price Target to $13 From $21, Maintains Overweight Rating	MT
22-03-01	Ladenburg Thalmann Initiates NextCure at Buy With $16 Price Target	MT
21-11-05	Needham Adjusts Price Target on NextCure to $14 from $30, Keeps Buy Rating	MT
21-08-09	NextCure : Piper Sandler Adjusts NextCure's Price Target to $21 From $26, Maintains Overweight Rating	MT
21-03-05	NextCure : Truist Securities Upgrades NextCure to Buy From Hold; Price Target is $19	MT
21-01-15	NextCure : BofA Securities Downgrades NextCure to Underperform From Neutral, Adjusts Price Target to $10 From $13	MT

More recommendations

Bio Therapeutic Drugs

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	NEXTCURE, INC.			-	-	+155.75%
	WUXI APPTEC CO., LTD.					+21.09%
	ARGENX SE					+11.95%
	INSMED INCORPORATED					+58.51%
	BIONTECH SE					+15.94%
	WUXI BIOLOGICS (CAYMAN) INC.					+16.61%
	GENMAB A/S					+12.11%
	PHARMAESSENTIA CORPORATION					+6.66%
	SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.					+26.36%
	EXELIXIS, INC.					-9.02%
	Average					+31.60%
	Weighted average by Cap.					+18.96%

See all sector performances

Analysts' Consensus

Sell

Consensus

Buy

Mean consensus

BUY

Number of Analysts

1

Last Close Price

7.820USD

Average target price

20.00USD

Spread / Average Target

+155.75%

High Price Target

20.00USD

Spread / Highest target

+155.75%

Low Price Target

20.00USD

Spread / Lowest Target

+155.75%

Analyst Consensus Detail

Consensus revision (last 18 months)

Stock Market
Stocks
NXTC Stock
Consensus NextCure, Inc.

The best tools reserved for subscribers to boost the performance of your investments!

×